Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (51-60 of 490) with videos related to

Pageof 49
Sort By:
Oncotarget|March 23, 2019
Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapiesLaura Hüser, Peter Altevogt, Jochen Utikal
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 29, 2016
Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patientsChristoffer Gebhardt, Ramtin Lichtenberger, Jochen Utikal
Cancers|November 28, 2013
Systemic therapy of non-resectable metastatic melanomaAzadeh Orouji, Sergij Goerdt, Jochen Utikal
Oncoimmunology|July 30, 2016
Predictive immune markers in advanced melanoma patients treated with ipilimumabViktor Umansky, Jochen Utikal, Christoffer Gebhardt
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 5, 2014
From skin to other cell types of the bodyDaniel Novak, Kasia Weina, Jochen Utikal
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|June 17, 2021
[Management of malignant adnexal neoplasms of the skin]Pia Nagel, Verena Müller, Jochen Utikal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-upSelma Ugurel, Thomas Mentzel, Jochen Utikal, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Cancer Letters|January 22, 2020
Dormant tumor cells interact with memory CD8<sup>+</sup> T cells in RET transgenic mouse melanoma modelFernando Flores-Guzmán, Jochen Utikal, Viktor Umansky
European Journal of Cancer (Oxford, England : 1990)|January 6, 2024
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREGCorinna Kochanek, Catharina Gilde, Lisa Zimmer, et al.
Pageof 49

Showing results (51-60 of 490) with videos related to

Sort By:
Pageof 49
Oncotarget|March 23, 2019
Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapiesLaura Hüser, Peter Altevogt, Jochen Utikal
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 29, 2016
Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patientsChristoffer Gebhardt, Ramtin Lichtenberger, Jochen Utikal
Cancers|November 28, 2013
Systemic therapy of non-resectable metastatic melanomaAzadeh Orouji, Sergij Goerdt, Jochen Utikal
Oncoimmunology|July 30, 2016
Predictive immune markers in advanced melanoma patients treated with ipilimumabViktor Umansky, Jochen Utikal, Christoffer Gebhardt
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 5, 2014
From skin to other cell types of the bodyDaniel Novak, Kasia Weina, Jochen Utikal
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|June 17, 2021
[Management of malignant adnexal neoplasms of the skin]Pia Nagel, Verena Müller, Jochen Utikal
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-upSelma Ugurel, Thomas Mentzel, Jochen Utikal, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Cancer Letters|January 22, 2020
Dormant tumor cells interact with memory CD8<sup>+</sup> T cells in RET transgenic mouse melanoma modelFernando Flores-Guzmán, Jochen Utikal, Viktor Umansky
European Journal of Cancer (Oxford, England : 1990)|January 6, 2024
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREGCorinna Kochanek, Catharina Gilde, Lisa Zimmer, et al.
Pageof 49